154 related articles for article (PubMed ID: 30529129)
1. The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines.
Alcolea PJ; Alonso A; Larraga V
Plasmid; 2019 Jan; 101():35-42. PubMed ID: 30529129
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
4. A pestivirus DNA vaccine based on a non-antibiotic resistance Escherichia coli essential gene marker.
El-Attar LM; Scott S; Goh S; Good L
Vaccine; 2012 Feb; 30(9):1702-9. PubMed ID: 22212129
[TBL] [Abstract][Full Text] [Related]
5. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
[TBL] [Abstract][Full Text] [Related]
6. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
7. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
Sharma A; Madhubala R
J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
[TBL] [Abstract][Full Text] [Related]
10. A non-replicative antibiotic resistance-free DNA vaccine delivered by the intranasal route protects against canine leishmaniasis.
Alonso A; Alcolea PJ; Larraga J; Peris MP; Esteban A; Cortés A; Ruiz-García S; Castillo JA; Larraga V
Front Immunol; 2023; 14():1213193. PubMed ID: 37790927
[No Abstract] [Full Text] [Related]
11. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
[TBL] [Abstract][Full Text] [Related]
12. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
13. Plasmid selection in Escherichia coli using an endogenous essential gene marker.
Goh S; Good L
BMC Biotechnol; 2008 Aug; 8():61. PubMed ID: 18694482
[TBL] [Abstract][Full Text] [Related]
14. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
[TBL] [Abstract][Full Text] [Related]
16. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
Sukumaran B; Tewary P; Saxena S; Madhubala R
Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
[TBL] [Abstract][Full Text] [Related]
18. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
[TBL] [Abstract][Full Text] [Related]
19. Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.
Kashino SS; Abeijon C; Qin L; Kanunfre KA; Kubrusly FS; Silva FO; Costa DL; Campos D; Costa CH; Raw I; Campos-Neto A
Parasite Immunol; 2012 Jul; 34(7):360-71. PubMed ID: 22443237
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
